Ottobock Strengthens Investment in NeuroTech Company ONWARD® Medical

Ottobock SE & Co. KGaA has increased its investment in ONWARD Medical N.V., a European company developing therapies for spinal cord injuries and movement disabilities. On October 22, 2025, ONWARD Medical announced a successful capital increase, raising EUR 50.9 million. Ottobock, as a cornerstone investor, contributed EUR 10 million, maintaining its position as the largest shareholder.

This investment follows Ottobock's initial EUR 22.5 million investment in October 2024. ONWARD Medical has since launched the ARC-EX System in the US, with studies indicating a 90% improvement in upper limb function among participants. Funds will support the commercialization of ARC-EX and the development of the ARC-IM System targeting various spinal cord injury complications.